{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:01:06Z","timestamp":1790438466366,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117336","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:06:05Z","timestamp":1787616365000},"page":"117336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ability of KBTBD10 to inhibit non-small cell lung cancer mediated by LINC01585"],"prefix":"10.1016","volume":"188","author":[{"given":"Xizi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqian","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117336_bb0005","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/S0140-6736(19)32795-3","article-title":"The Lancet. Lung cancer: some progress, but still a lot more to do","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.117336_bb0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117336_bb0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117336_bb0020","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?","volume":"16","author":"Qiao","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117336_bb0025","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ebiom.2019.02.049","article-title":"KRAS-mutant non-small cell lung cancer: converging small molecules and immune checkpoint inhibition","volume":"41","author":"Adderley","year":"2019","journal-title":"EBiomedicine"},{"key":"10.1016\/j.intimp.2026.117336_bb0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117336_bb0035","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1158\/1078-0432.CCR-20-4084","article-title":"Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)","volume":"27","author":"Bertino","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117336_bb0040","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.117336_bb0045","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2026.117336_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/resp.13870","article-title":"Radiotherapy treatment for lung cancer: current status and future directions","volume":"25","author":"Vinod","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.intimp.2026.117336_bb0055","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1093\/hmg\/ddz078","article-title":"Dysregulation of NRAP degradation by KLHL41 contributes to pathophysiology in nemaline myopathy","volume":"28","author":"Jirka","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.intimp.2026.117336_bb0060","first-page":"5105","article-title":"The roles of KLHL family members in human cancers","volume":"12","author":"Ye","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117336_bb0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","article-title":"Ubiquitination in the regulation of inflammatory cell death and cancer","volume":"28","author":"Cockram","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.intimp.2026.117336_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13046-020-01819-0","article-title":"Lnc-GAN1 expression is associated with good survival and suppresses tumor progression by sponging mir-26a-5p to activate PTEN signaling in non-small cell lung cancer","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117336_bb0075","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12943-018-0843-8","article-title":"Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a","volume":"17","author":"Xin","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117336_bb0080","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1038\/s41388-021-01769-7","article-title":"Long non-coding RNA LEISA promotes progression of lung adenocarcinoma via enhancing interaction between STAT3 and IL-6 promoter","volume":"40","author":"Wu","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.117336_bb0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.117336_bb0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13578-020-00499-9","article-title":"KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K\/PD-L1 axis activity","volume":"10","author":"Jiang","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.intimp.2026.117336_bb0095","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1186\/s12885-022-10426-5","article-title":"Autophagy inhibition and reactive oxygen species elimination by acetyl-CoA acetyltransferase 1 through fused in sarcoma protein to promote prostate cancer","volume":"22","author":"Guan","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.117336_bb0100","first-page":"1791","article-title":"Elevated FUS\/TLS expression is negatively associated with E-cadherin expression and prognosis of patients with non-small cell lung cancer","volume":"16","author":"Xiong","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2026.117336_bb0105","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210151","article-title":"E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer","volume":"218","author":"Li","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.117336_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-2267-9","article-title":"PABPC1-induced stabilization of BDNF-AS inhibits malignant progression of glioblastoma cells through STAU1-mediated decay","volume":"11","author":"Su","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.117336_bb0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/15476286.2020.1868753","article-title":"LARP1 and LARP4: up close with PABP for mRNA 3\u2032 poly(a) protection and stabilization","volume":"18","author":"Mattijssen","year":"2021","journal-title":"RNA Biol."},{"key":"10.1016\/j.intimp.2026.117336_bb0120","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/cancers12051107","article-title":"STAT3: versatile functions in non-small cell lung cancer","volume":"12","author":"Mohrherr","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117336_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2017.12.003","article-title":"The role of STAT3 in leading the crosstalk between human cancers and the immune system","volume":"415","author":"Wang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.117336_bb0130","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/s41418-019-0460-0","article-title":"Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65\/STAT3-CSN5-PD-L1 pathway","volume":"27","author":"Liu","year":"2020","journal-title":"Cell Death Differ."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:38:44Z","timestamp":1790437124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":26,"alternative-id":["S1567576926011835"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117336","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ability of KBTBD10 to inhibit non-small cell lung cancer mediated by LINC01585","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117336"}}